Merck cautiously steps into the PD-(L)1/CTLA-4 checkpoint fray. But should it ‘go big or go home’ instead?
Merck’s strategy on developing its PD-1 checkpoint drug Keytruda could be summarized as: If we have any kind of a shot at a legitimate target …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
